Arrowhead Pharmaceuticals 将来の成長

Future 基準チェック /06

Arrowhead Pharmaceuticals利益と収益がそれぞれ年間3.1%と6.7%増加すると予測されています。EPS は年間減少すると予想されています。自己資本利益率は 3 年後に-67.3% 0.3%なると予測されています。

主要情報

3.1%

収益成長率

-0.25%

EPS成長率

Biotechs 収益成長	22.6%
収益成長率	6.7%
将来の株主資本利益率	-67.27%
アナリストカバレッジ	Good
最終更新日	20 Feb 2026

今後の成長に関する最新情報

Recent updates

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

Feb 12

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Jan 06

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Dec 02

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Oct 07

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Aug 21

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

May 18 Transition to a commercial stage with plozasiran could significantly boost future revenues and improve margins through successful product launches.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

May 14

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Feb 10

業績と収益の成長予測

NasdaqGS:ARWR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2028	499	-494	-414	-432	8
9/30/2027	316	-609	-488	-537	12
9/30/2026	448	-494	-183	-271	13
12/31/2025	1,091	202	322	339	N/A
9/30/2025	829	-2	157	180	N/A
6/30/2025	573	-148	-18	22	N/A
3/31/2025	545	-144	10	61	N/A
12/31/2024	3	-640	-572	-491	N/A
9/30/2024	4	-599	-604	-463	N/A
6/30/2024	20	-539	-533	-352	N/A
3/31/2024	35	-471	-470	-257	N/A
12/31/2023	182	-297	-403	-196	N/A
9/30/2023	241	-205	-331	-154	N/A
6/30/2023	256	-181	-342	-197	N/A
3/31/2023	273	-150	-353	-245	N/A
12/31/2022	278	-155	-236	-150	N/A
9/30/2022	243	-176	-189	-136	N/A
6/30/2022	250	-154	-120	-91	N/A
3/31/2022	263	-112	-75	-52	N/A
12/31/2021	144	-183	124	149	N/A
9/30/2021	138	-141	148	171	N/A
6/30/2021	108	-126	167	184	N/A
3/31/2021	89	-110	165	181	N/A
12/31/2020	80	-103	-123	-111	N/A
9/30/2020	88	-85	-108	-96	N/A
6/30/2020	124	-24	-89	-71	N/A
3/31/2020	139	10	-46	-27	N/A
12/31/2019	164	53	-34	-19	N/A
9/30/2019	169	68	N/A	173	N/A
6/30/2019	137	46	N/A	157	N/A
3/31/2019	95	10	N/A	132	N/A
12/31/2018	47	-29	N/A	136	N/A
9/30/2018	16	-54	N/A	-47	N/A
6/30/2018	14	-54	N/A	-54	N/A
3/31/2018	22	-44	N/A	-50	N/A
12/31/2017	31	-35	N/A	-49	N/A
9/30/2017	31	-34	N/A	-24	N/A
6/30/2017	23	-46	N/A	-25	N/A
3/31/2017	13	-60	N/A	-33	N/A
12/31/2016	4	-75	N/A	-33	N/A
9/30/2016	0	-82	N/A	-64	N/A
6/30/2016	0	-84	N/A	-66	N/A
3/31/2016	0	-81	N/A	-61	N/A
12/31/2015	0	-89	N/A	-63	N/A
9/30/2015	0	-92	N/A	-66	N/A
6/30/2015	0	-90	N/A	-65	N/A
3/31/2015	0	-85	N/A	-61	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ARWRの予測収益成長率 (年間3.1% ) は貯蓄率 ( 3.4% ) を下回っています。

収益対市場: ARWRの収益 ( 3.1% ) US市場 ( 15.5% ) よりも低い成長が予測されています。

高成長収益: ARWRの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ARWRの収益 ( 6.7% ) US市場 ( 10.2% ) よりも低い成長が予測されています。

高い収益成長: ARWRの収益 ( 6.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ARWR 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/03/04 08:17
終値	2026/03/04 00:00
収益	2025/12/31
年間収益	2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成する分析モデルの詳細は当社の Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや YouTubeのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Arrowhead Pharmaceuticals, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。27

アナリスト	機関
Ying Huang	Barclays
William Pickering	Bernstein
Jason Matthew Gerberry	BofA Global Research

Arrowhead Pharmaceuticals 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 15% to US$75.91

Price target increased by 7.4% to US$59.25

Consensus estimates of losses per share improve by 87%

Price target increased by 16% to US$55.00

Consensus EPS estimates fall by 221%

Recent updates

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

Consensus revenue estimates increase by 12%, EPS downgraded

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Arrowhead Pharmaceuticals, Inc. to Report Q1, 2026 Results on Feb 05, 2026

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 19, 2026

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.998502 million.

Price target increased by 15% to US$75.91

Arrowhead Pharmaceuticals Announces Nmpa Approval of Redemplo (Plozasiran) for Familial Chylomicronemia Syndrome in China

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Arrowhead Pharmaceuticals Announces Health Canada Approval of Redemplo to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Chairman notifies of intention to sell stock

Chairman recently sold US$12m worth of stock

Chairman notifies of intention to sell stock

Now 20% overvalued after recent price rise

Independent Director recently sold US$992k worth of stock

Price target increased by 7.4% to US$59.25

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Independent Director recently sold US$493k worth of stock

Arrowhead Pharmaceuticals, Inc. Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

Consensus estimates of losses per share improve by 87%

Price target increased by 16% to US$55.00

Arrowhead Pharmaceuticals, Inc Announces FDA Approval of Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Consensus EPS estimates fall by 221%

Arrowhead Pharmaceuticals, Inc. Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Files Complaint for Patent Infringement Against Arrowhead Pharmaceuticals, Inc

Consensus EPS estimates have been downgraded.

Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other Tauopathies

No longer forecast to breakeven

Chief Medical Officer and Head of R&D notifies of intention to sell stock

Consensus EPS estimates fall by 65%

Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified

Consensus EPS estimates fall from profit to US$0.11 loss, revenue upgraded

No longer forecast to breakeven

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Forecast to breakeven in 2025

Arrowhead Pharmaceuticals Completes Enrollment in Shasta-3, Shasta-4, and Muir-3 Phase 3 Studies of Plozasiran

Consensus EPS estimates increase by 17%

Arrowhead Pharmaceuticals Initiates Phase 1/2A Study of Aro-Alk7 for the Treatment of Obesity

Insufficient new directors

Consensus EPS estimates increase by 168%

Forecast to breakeven in 2025

Consensus revenue estimates increase by 112%

Plozasiran Launch Will Transition Biotech Focus Despite Regulatory Hurdles

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry

New major risk - Revenue and earnings growth

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective May 13, 2025

Chairman recently sold US$1.5m worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Is Finally Arriving

Chairman recently sold US$775k worth of stock

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Chairman notifies of intention to sell stock

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. Presents Preclinical Data on Aro-Alk7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns

Arrowhead Pharmaceuticals, Inc. Appoints Douglas Ingram as Director

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2025